Sponsors may be seeing the US FDA's ANDA assessment system running at full power once again, as it posted a record for full and tentative approvals in July.
Indeed, following a crash in approval volume in the second quarter, it now appears the recovery is complete and the Office of Generic Drugs may be establishing another new normal.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?